- In October 2024, Amicus Therapeutics announced a settlement regarding its drug Galafold (migalastat), which treats Fabry disease. The settlement resolves ongoing patent disputes and confirms the continuation of the drug’s marketing without litigation interference. This agreement with multiple parties aims to provide stability for Galafold’s availability and development while protecting intellectual property rights
- In June 2024, Amicus Therapeutics was honored with the Prix Galien UK Award for its innovative treatment, Pombiliti (miglustat), for the management of Fabry disease. The award recognizes excellence in pharmaceutical innovation and emphasizes the impact of Pombiliti in improving the lives of patients with rare genetic conditions. This accolade highlights Amicus’ leadership in rare disease therapies
- In April 2024, Forge Biologics announced it would present nine times at the ASGCT 27th Annual Meeting in May 2024, including a late-breaking oral presentation and three technical sessions. Presentations will cover process development, molecular advancements, and clinical updates, including a significant clinical result for FBX-101 in Krabbe disease
- In November 2023, Chiesi Group has been reaccredited as a Great Place to Work-Certified organization across multiple regions, including Italy, Australia, the US, and others. With an 85% response rate from employees, Chiesi achieved an 83% overall satisfaction rate, reflecting its commitment to fostering a positive, inclusive, and collaborative work environment focused on employee well-being and growth
- In January 2024, Denali Therapeutics Inc., a biopharmaceutical company developing therapies to cross the blood-brain barrier for treating neurodegenerative and lysosomal storage diseases, announced progress and milestones for 2024. CEO Ryan Watts, Ph.D., highlighted these developments during a corporate presentation at the 42nd Annual J.P. Morgan Healthcare Conference on January 9th
